These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 9124202

  • 1. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
    Recchia F, De Filippis S, Torchio P, Rea S, Gulino A, Quaglino D, Frati L.
    Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors.
    Recchia F, Accorsi P, Bonfini T, De Filippis S, Grimaldi M, Corrao G, Rosselli M, Amiconi G, Iacone A, Rea S.
    J Interferon Cytokine Res; 2000 Feb; 20(2):171-7. PubMed ID: 10714552
    [Abstract] [Full Text] [Related]

  • 3. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A, Crown JP, Motzer RJ, Reich LM, Heller G, Moore MP, Hamilton N, Yao TJ, Heelan RT, Schneider JG.
    Cancer; 1993 Apr 15; 71(8):2515-21. PubMed ID: 8095854
    [Abstract] [Full Text] [Related]

  • 4. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC.
    J Clin Oncol; 1997 Feb 15; 15(2):674-83. PubMed ID: 9053493
    [Abstract] [Full Text] [Related]

  • 5. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH.
    J Pediatr Hematol Oncol; 2001 Jan 15; 23(1):30-8. PubMed ID: 11196267
    [Abstract] [Full Text] [Related]

  • 6. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D, Wasserheit C, Schneider J, Hakes T, Reich L, Curtin J, Yao TJ, Markman M, Norton L, Crown J.
    Cancer Res; 1994 Dec 01; 54(23):6137-42. PubMed ID: 7525055
    [Abstract] [Full Text] [Related]

  • 7. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May 01; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb 01; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov 01; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC, Neidhart JA, Triozzi P, Verma S, Nemunaitis J, Quick DP, Mayernik DG, Oette DH, Haynes FA, Holcenberg J.
    Am J Hematol; 1996 Apr 01; 51(4):289-95. PubMed ID: 8602629
    [Abstract] [Full Text] [Related]

  • 14. Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.
    Toner GC, Green M, Bishop JF, McKendrick J, Cebon J, Sheridan WP, Lockbaum P, O'Byrne J, Fox RM.
    Am J Clin Oncol; 1998 Jun 01; 21(3):263-9. PubMed ID: 9626795
    [Abstract] [Full Text] [Related]

  • 15. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG.
    Blood; 1997 May 01; 89(9):3118-28. PubMed ID: 9129014
    [Abstract] [Full Text] [Related]

  • 16. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, Mela GS, Sessarego M, Gobbi M, Patrone F.
    J Clin Oncol; 1999 Apr 01; 17(4):1296. PubMed ID: 10561192
    [Abstract] [Full Text] [Related]

  • 17. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH, Christiansen NP, Fay JP, Brown R, Herzig R, Frankel S, Blumenson L, Herzig GP.
    Exp Hematol; 1996 Oct 01; 24(12):1363-8. PubMed ID: 8913281
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.
    Gynecol Oncol; 2000 May 01; 77(2):271-7. PubMed ID: 10785477
    [Abstract] [Full Text] [Related]

  • 19. Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.
    Quittet P, Ceballos P, Lopez E, Lu ZY, Latry P, Becht C, Legouffe E, Fegueux N, Exbrayat C, Pouessel D, Rouillé V, Daures JP, Klein B, Rossi JF.
    Bone Marrow Transplant; 2006 Aug 01; 38(4):275-84. PubMed ID: 16883311
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun 01; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.